<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03977779</url>
  </required_header>
  <id_info>
    <org_study_id>ARCHIMEDE-PANCREAS-IPC</org_study_id>
    <nct_id>NCT03977779</nct_id>
  </id_info>
  <brief_title>Evaluation of the Use of a Biodegradable Endoprothesis in the Prevention of Post-Endoscopic Retrograde CholoangioPancreatography Pancreatitis</brief_title>
  <acronym>ARCHIMEDE</acronym>
  <official_title>Prospective Evaluation of the Use of a Biodegradable Endoprothesis in the Prevention of Post-Endoscopic Retrograde CholoangioPancreatography Pancreatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Paoli-Calmettes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Paoli-Calmettes</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The use of an endoprothesis in a pancreatic duct is a measure to minimize the incidence and
      severity of Post-Endoscopic Retrograde CholoangioPancreatography Pancreatitis. In this study
      we will evaluate the use of a Biodegradable Endoprothesis: Archimede Fast Biodegradable
      Pancreatic Stent in patients with high risk of Post-Endoscopic Retrograde
      CholoangioPancreatography Pancreatitis.The ARCHIMEDES Fast biodegradable pancreatic stent
      will be placed during the Endoscopic Retrograde CholoangioPancreatography. The efficacy and
      the security of the device will be evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 10, 2020</start_date>
  <completion_date type="Anticipated">November 10, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 10, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with a complete clearance of the biodegradable stent</measure>
    <time_frame>Day 15</time_frame>
    <description>The degradation of the stent will be evaluated both duodenoscopy/fluoroscopy and endoscopy 15 days after its placement</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Obstructive Jaundice</condition>
  <condition>Biliary Stricture</condition>
  <condition>Sphincter of Oddi Dysfunction</condition>
  <arm_group>
    <arm_group_label>Prophylactic biodegradable pancreatic stent placement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placement of ARCHIMEDES fast biodegradable stent during the Endoscopic Retrograde CholoangioPancreatography</intervention_name>
    <description>The ARCHIMEDES Fast biodegradable pancreatic stent will be placed during the Endoscopic Retrograde CholoangioPancreatography</description>
    <arm_group_label>Prophylactic biodegradable pancreatic stent placement</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age&gt;18 years

          -  Patients at risk of developing a Post-Endoscopic Retrograde CholoangioPancreatography
             Pancreatitis (procedure and/or patient-related risk factors

        Exclusion Criteria:

          -  Pregnant or breastfeeding women

          -  Recent diagnosis (&lt;1 month) of acute pancreatitis

          -  contraindication to endoscopy

          -  Hypersensitivity to indomethacine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dominique Genre, MD</last_name>
    <phone>+33491223778</phone>
    <email>drci.up@ipc.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marc Giovannini, MD</last_name>
    <email>giovanninim@ipc.unicancer.fr</email>
  </overall_contact_backup>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 5, 2019</study_first_submitted>
  <study_first_submitted_qc>June 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2019</study_first_posted>
  <last_update_submitted>February 13, 2020</last_update_submitted>
  <last_update_submitted_qc>February 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>biodegradable stent</keyword>
  <keyword>Post-Endoscopic Retrograde CholoangioPancreatography Pancreatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
    <mesh_term>Sphincter of Oddi Dysfunction</mesh_term>
    <mesh_term>Jaundice</mesh_term>
    <mesh_term>Jaundice, Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

